Area of research
Genetics · Pathology and Forensic Medicine
Research interest
Research interests include Genetic Associations and Epidemiology, BRCA gene mutations in cancer, Genetic factors in colorectal cancer, and Cardiac Valve Diseases and Treatments.
Identification of <i>TMEM106B</i> as a Shared Potential Drug Target for Depression and Stroke Through Comprehensive Genetic Analyses.
Risk factors for prostate cancer: An umbrella review of prospective observational studies and mendelian randomization analyses
Risk factors for prostate cancer: An umbrella review of prospective observational studies and mendelian randomization analyses.
Investigating the relationship between depression and breast cancer: observational and genetic analyses
Epidemiological and genetic evidence for the relationship between ABO blood group and human cancer.
A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis
Additional Evidence for the Relationship Between Type 2 Diabetes and Stroke Through Observational and Genetic Analyses.
Migraine, chronic kidney disease and kidney function: observational and genetic analyses.
Targeting fibrosis: mechanisms and clinical trials
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial
Alcohol consumption, blood DNA methylation and breast cancer: a Mendelian randomisation study
Abstract CT038: Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage SCLC: A phase 3 trial
A phase 1 trial of the PARP inhibitor fuzuloparib in combination with the anti-angiogenic apatinib in recurrent ovarian or triple-negative breast cancer.
Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial
Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study)
An Open-label, Multicenter, Single-arm, Phase II Study of Fluzoparib in Patients with Germline <i>BRCA1/2</i> Mutation and Platinum-sensitive Recurrent Ovarian Cancer
Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations
Large-Scale Genome-Wide Association Study of East Asians Identifies Loci Associated With Risk for Colorectal Cancer
Identification of Susceptibility Loci and Genes for Colorectal Cancer Risk
Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry
Genome-wide association study of colorectal cancer identifies six new susceptibility loci
Large-scale genetic study in East Asians identifies six new loci associated with colorectal cancer risk
Genome-wide association analysis in East Asians identifies breast cancer susceptibility loci at 1q32.1, 5q14.3 and 15q26.1
Meta-analysis of genome-wide association studies of adult height in East Asians identifies 17 novel loci
Common genetic determinants of breast-cancer risk in East Asian women: a collaborative study of 23 637 breast cancer cases and 25 579 controls
Identification of Genetic Susceptibility Loci for Colorectal Tumors in a Genome-Wide Meta-analysis
Genome-wide association analyses in east Asians identify new susceptibility loci for colorectal cancer
Genome-Wide Association Study in East Asians Identifies Novel Susceptibility Loci for Breast Cancer